MedTrace Logo

Caffeine Supplementation on Movement Patterns and Reactive Agility in Rugby Sevens Matches

NCT06612463 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-10-01

No results posted yet for this study

Summary

Caffeine is widely used by rugby players for its performance-enhancing effects. The main questions it aims to answer are: (1) the impact of caffeine supplementation on various performance metrics, including distance covered at different speeds, acceleration, deceleration, collisions, and repeated high-intensity efforts; and (2) reactive agility, across four matches over two consecutive days in collegiate male rugby sevens players.A position-matched, double-blind, randomized crossover design was employed, with six male collegiate rugby players (mean height: 1.78 ± 0.09 m, mean weight: 81.3 ± 9.2 kg) participating in two trials. Each trial consisted of a two-day tournament, with two matches per day. Movement was monitored using global positioning system units.

Conditions

  • Exercise

Interventions

DIETARY_SUPPLEMENT

Caffeine 6mg/kg

In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day

DIETARY_SUPPLEMENT

Placebo

In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day

Sponsors & Collaborators

  • National Taiwan Sport University

    lead OTHER

Principal Investigators

  • Chen-Kang Chang, PhD · National Taiwan University of Sport

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2023-10-30
Completion
2024-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612463 on ClinicalTrials.gov